ZEPOSIA (ozanimod) - Relapsing-remitting multiple sclerosis (RRMS)

Opinions on drugs - Posted on Jun 12 2025

Reason for request

Reassessment

Summary of opinion

Favourable opinion for maintenance of reimbursement in the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.

Clinical Benefit

Substantial

The clinical benefit of ZEPOSIA (ozanimod) remains substantial in the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.

Clinical Added Value

Comments without ASMR value

The Committee deems that the data provided in the context of this reassessment are not of a nature to modify the assessment of the clinical added value expressed in the previous opinion of 2 December 2020.